InterPAD - DETAILS

Eicosapentaenoic acid, Timnodonic acid, Icosapent, 10417-94-4, Icosapentaenoic acid, EPA, cis-5,8,11,14,17-Eicosapentaenoic acid, Icosapento, Icosapentum, (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid, Miraxion, 5,8,11,14,17-EICOSAPENTAENOIC ACID, eicosapentaenoate, 5Z,8Z,11Z,14Z,17Z-Eicosapentaenoic acid, (all-Z)-5,8,11,14,17-Eicosapentaenoic acid, Icosapent [INN], Eicosapentanoic acid, (5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-eicosapentaenoic acid, Eye Q, Eye-Q, Ropufa 70, Incromega e 7010sr, CCRIS 3279, AAN7QOV9EA, UNII-AAN7QOV9EA, EPA 45G, (5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid, 5,8,11,14,17-Icosapentaenoic acid, EPA [drug], CHEBI:28364, (5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate, (5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid, Icosapentum [INN-Latin], Icosapento [INN-Spanish], C20:5n-3,6,9,12,15, C20:5 (n-3), CHEMBL460026, DTXSID9041023, all-cis-5,8,11,14,17-icosapentaenoic acid, all-cis-5,8,11,14,17-eicosapentaenoic acid, all-cis-icosa-5,8,11,14,17-pentaenoic acid, Icosapent (INN), cis-Delta(5,8,11,14,17)-eicosapentaenoic acid, 5,8,11,14,17-Eicosapentaenoic acid, (all-Z)-, Eicosapentaenoic acid (c20:5 n3), EPA;Timnodonic acid, Icosapentaenoate, (all-Z)-delta5,8,11,14,17-Eicosapentaenoic acid, MFCD00065716, EPA (drug), cis-5,8,11,14,17-EPA, FA 20:5, NCGC00161344-03, 5,8,11,14,17-Eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z)-, EICOSAPENTAENOIC ACID (20:5 n-3), Icosapentum (INN-Latin), Icosapento (INN-Spanish), all cis-5,8,11,14,17-Eicosapentaenoic Acid, Eicosa-5Z,8Z,11Z,14Z,17Z-pentaenoic Acid (20:5, n-3), (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate, Timnodonate, 3gwx, RELIVEN, EPA-FFA, all-cis-icosapentaenoate, ICOSAPENT (EPA), all-cis-icosapentaenoic acid, SCHEMBL20469, BSPBio_001328, BML3-B01, GTPL3362, DTXCID7021023, EICOSAPENTAENOIC ACID [MI], HMS1361C10, HMS1791C10, HMS1989C10, HMS3402C10, HMS3649D19, HY-B0660, 5,8,11,14,17-Icosapentaenoate, Tox21_111991, 5,8,11,14,17-Eicosapentaenoate, BDBM50242349, EICOSAPENTAENOIC ACID [VANDF], LMFA01030759, s6476, EICOSAPENTAENOIC ACID [MART.], AKOS027470327, EICOSAPENTAENOIC ACID [USP-RS], EICOSAPENTAENOIC ACID [WHO-DD], CCG-207957, CCG-208136, DB00159, cis-5,8,11,14,17-eicosapentaenoate, IDI1_033798, NCGC00161344-01, NCGC00161344-02, NCGC00161344-04, NCGC00161344-07, 5Z,8Z,11Z,14Z,17Z-Eicosapentaenoate, AC-31072, AS-53730, CAS-10417-94-4, E0441, FT-0621978, NS00010730, 5,8,11,14,17-Eicosapentaenoic acid (6CI), all cis-5,8,11,14,17-Icosapentaenoic Acid, C06428, D08061, P16966, EN300-7403855, (all-cis)-5,8,11,14,17-Eicosapentaenoic acid, EICOSAPENTAENOIC ACID (EPA) (C20:5 N3), L001256, Q409990, SR-01000946647, FA(20:5(5Z,8Z,11Z,14Z,17Z)), J-001125, SR-01000946647-1, z,z,z,z,z-eicosa-5,8,11,14,17-pentaenoic acid, (Z,Z,Z,Z,Z)-5,8,11,14,17-eicosapentaenoic acid, BRD-K47192521-001-02-1, cis-5,8,11,14,17-Eicosapentaenoic acid, >=99%, 7F8BF016-B146-4F72-A52E-B9298BA3A9AB, C20H30O2 (cis-5,8,11,14,17-eicosapentaenoic acid), Eicosapentaenoic acid, 5,8,11,14,17-(Z,Z,Z,Z,Z)-, 5,8,11,14,17-Eicosapentaenoic acid, (all-Z)- (8CI), cis-5,8,11,14,17-Eicosapentaenoic acid, >=85%, liquid, cis-5,8,11,14,17-Eicosapentaenoic acid, analytical standard, (5Z,8Z,11 Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid, (5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenoic acid, cis, cis, cis, cis, cis-eicosa-5,8,11,14,17-pentaenoic acid, 5,8,11,14,17-Eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z)- (9CI), 25377-48-4, cis-5,8,11,14,17-Eicosapentaenoic acid, 500 mug/mL in ethanol, certified reference material

Name	Eicosapentaenoic acid
PubChem CID	446284
Molecular Weight	302.5g/mol
Synonyms	Eicosapentaenoic acid, Timnodonic acid, Icosapent, 10417-94-4, Icosapentaenoic acid, EPA, cis-5,8,11,14,17-Eicosapentaenoic acid, Icosapento, Icosapentum, (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid, Miraxion, 5,8,11,14,17-EICOSAPENTAENOIC ACID, eicosapentaenoate, 5Z,8Z,11Z,14Z,17Z-Eicosapentaenoic acid, (all-Z)-5,8,11,14,17-Eicosapentaenoic acid, Icosapent [INN], Eicosapentanoic acid, (5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-eicosapentaenoic acid, Eye Q, Eye-Q, Ropufa 70, Incromega e 7010sr, CCRIS 3279, AAN7QOV9EA, UNII-AAN7QOV9EA, EPA 45G, (5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid, 5,8,11,14,17-Icosapentaenoic acid, EPA [drug], CHEBI:28364, (5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate, (5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid, Icosapentum [INN-Latin], Icosapento [INN-Spanish], C20:5n-3,6,9,12,15, C20:5 (n-3), CHEMBL460026, DTXSID9041023, all-cis-5,8,11,14,17-icosapentaenoic acid, all-cis-5,8,11,14,17-eicosapentaenoic acid, all-cis-icosa-5,8,11,14,17-pentaenoic acid, Icosapent (INN), cis-Delta(5,8,11,14,17)-eicosapentaenoic acid, 5,8,11,14,17-Eicosapentaenoic acid, (all-Z)-, Eicosapentaenoic acid (c20:5 n3), EPA;Timnodonic acid, Icosapentaenoate, (all-Z)-delta5,8,11,14,17-Eicosapentaenoic acid, MFCD00065716, EPA (drug), cis-5,8,11,14,17-EPA, FA 20:5, NCGC00161344-03, 5,8,11,14,17-Eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z)-, EICOSAPENTAENOIC ACID (20:5 n-3), Icosapentum (INN-Latin), Icosapento (INN-Spanish), all cis-5,8,11,14,17-Eicosapentaenoic Acid, Eicosa-5Z,8Z,11Z,14Z,17Z-pentaenoic Acid (20:5, n-3), (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate, Timnodonate, 3gwx, RELIVEN, EPA-FFA, all-cis-icosapentaenoate, ICOSAPENT (EPA), all-cis-icosapentaenoic acid, SCHEMBL20469, BSPBio_001328, BML3-B01, GTPL3362, DTXCID7021023, EICOSAPENTAENOIC ACID [MI], HMS1361C10, HMS1791C10, HMS1989C10, HMS3402C10, HMS3649D19, HY-B0660, 5,8,11,14,17-Icosapentaenoate, Tox21_111991, 5,8,11,14,17-Eicosapentaenoate, BDBM50242349, EICOSAPENTAENOIC ACID [VANDF], LMFA01030759, s6476, EICOSAPENTAENOIC ACID [MART.], AKOS027470327, EICOSAPENTAENOIC ACID [USP-RS], EICOSAPENTAENOIC ACID [WHO-DD], CCG-207957, CCG-208136, DB00159, cis-5,8,11,14,17-eicosapentaenoate, IDI1_033798, NCGC00161344-01, NCGC00161344-02, NCGC00161344-04, NCGC00161344-07, 5Z,8Z,11Z,14Z,17Z-Eicosapentaenoate, AC-31072, AS-53730, CAS-10417-94-4, E0441, FT-0621978, NS00010730, 5,8,11,14,17-Eicosapentaenoic acid (6CI), all cis-5,8,11,14,17-Icosapentaenoic Acid, C06428, D08061, P16966, EN300-7403855, (all-cis)-5,8,11,14,17-Eicosapentaenoic acid, EICOSAPENTAENOIC ACID (EPA) (C20:5 N3), L001256, Q409990, SR-01000946647, FA(20:5(5Z,8Z,11Z,14Z,17Z)), J-001125, SR-01000946647-1, z,z,z,z,z-eicosa-5,8,11,14,17-pentaenoic acid, (Z,Z,Z,Z,Z)-5,8,11,14,17-eicosapentaenoic acid, BRD-K47192521-001-02-1, cis-5,8,11,14,17-Eicosapentaenoic acid, >=99%, 7F8BF016-B146-4F72-A52E-B9298BA3A9AB, C20H30O2 (cis-5,8,11,14,17-eicosapentaenoic acid), Eicosapentaenoic acid, 5,8,11,14,17-(Z,Z,Z,Z,Z)-, 5,8,11,14,17-Eicosapentaenoic acid, (all-Z)- (8CI), cis-5,8,11,14,17-Eicosapentaenoic acid, >=85%, liquid, cis-5,8,11,14,17-Eicosapentaenoic acid, analytical standard, (5Z,8Z,11 Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid, (5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenoic acid, cis, cis, cis, cis, cis-eicosa-5,8,11,14,17-pentaenoic acid, 5,8,11,14,17-Eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z)- (9CI), 25377-48-4, cis-5,8,11,14,17-Eicosapentaenoic acid, 500 mug/mL in ethanol, certified reference material
Drug Type	Small molecule
Formula	C₂₀H₃₀O₂
SMILES	CCC=CCC=CCC=CCC=CCC=CCCCC(=O)O
InChI	1S/C20H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-19H2,1H3,(H,21,22)/b4-3-,7-6-,10-9-,13-12-,16-15-
InChIKey	JAZBEHYOTPTENJ-JLNKQSITSA-N
CAS Number	10417-94-4
ChEMBL ID	CHEMBL460026
ChEBI ID	CHEBI:28364
TTD ID	D0Q5XX
Drug Bank ID	DB00159
KEGG ID	C06428
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Lycopene, Eicosapentaenoic acid
Partner Name	Lycopene
Disease Info	[ICD-11: 2B90]	Colon cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Up-regulation	Expression	BAX	hsa581
	Up-regulation	Expression	FAS	hsa355
	Down-regulation	Phosphorylation	MTOR	hsa2475
In Vitro Model	HT-29	Colon adenocarcinoma	Homo sapiens (Human)	CVCL_0320
Result	Our novel findings suggest that lycopene and EPA synergistically inhibited the growth of human colon cancer HT-29 cells even at low concentration. The inhibitory effects of lycopene and EPA on cell proliferation of human colon cancer HT-29 cells were, in part, associated with the down-regulation of the PI-3K/Akt/mTOR signaling pathway.